Subscribe
Share
Share
Embed
Listeners can expect to learn about:
• The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression
• The current IgAN treatment landscape
• The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial